As FDA weighs the creation of an Expanded Access Navigator program, an independent panel's leaders say written assurance that adverse events will not damage a drug's prospects for continued development or approval would have far more impact in enabling pre-approval access for desperate patients.
FDA should "publish a statement assuring companies that the agency understands serious adverse events can and will happen in compassionate use setting and that such events will not constitute a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?